July 9, 2020 / 8:40 PM / a month ago

BRIEF-Ziopharm Oncology Announces Initiation Of Phase 1 Trial Evaluating Rapid Personalized Manufacturing Car-T Technology In Patients With Relapsed Cd19+ Leukemias And Lymphomas

July 9 (Reuters) - ZIOPHARM Oncology Inc:

* ZIOPHARM ONCOLOGY ANNOUNCES INITIATION OF PHASE 1 TRIAL EVALUATING RAPID PERSONALIZED MANUFACTURING CAR-T TECHNOLOGY IN PATIENTS WITH RELAPSED CD19+ LEUKEMIAS AND LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below